| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 622 | 2024 | 2138 | 52.470 |
Why?
|
| Aging | 307 | 2023 | 1729 | 32.010 |
Why?
|
| Brain | 310 | 2023 | 1800 | 26.140 |
Why?
|
| Cognition Disorders | 234 | 2023 | 1057 | 25.550 |
Why?
|
| Cognitive Dysfunction | 188 | 2024 | 1089 | 24.260 |
Why?
|
| Cognition | 224 | 2023 | 1423 | 20.980 |
Why?
|
| Aged, 80 and over | 673 | 2024 | 5195 | 20.450 |
Why?
|
| Aged | 750 | 2024 | 10065 | 17.120 |
Why?
|
| Dementia | 110 | 2024 | 561 | 16.710 |
Why?
|
| Male | 797 | 2023 | 16479 | 14.220 |
Why?
|
| Humans | 1098 | 2024 | 31038 | 14.030 |
Why?
|
| Female | 796 | 2023 | 16985 | 13.910 |
Why?
|
| Neuropsychological Tests | 233 | 2023 | 1311 | 12.270 |
Why?
|
| Longitudinal Studies | 223 | 2023 | 1506 | 10.700 |
Why?
|
| Genetic Predisposition to Disease | 94 | 2022 | 464 | 9.840 |
Why?
|
| Cohort Studies | 228 | 2023 | 2040 | 9.440 |
Why?
|
| Amyloid beta-Peptides | 100 | 2023 | 329 | 9.030 |
Why?
|
| Parkinsonian Disorders | 36 | 2023 | 234 | 8.250 |
Why?
|
| Apolipoproteins E | 76 | 2023 | 270 | 7.680 |
Why?
|
| Apolipoprotein E4 | 67 | 2023 | 258 | 7.640 |
Why?
|
| Genome-Wide Association Study | 117 | 2023 | 320 | 7.630 |
Why?
|
| Polymorphism, Single Nucleotide | 95 | 2022 | 318 | 6.480 |
Why?
|
| Memory | 56 | 2021 | 330 | 6.400 |
Why?
|
| tau Proteins | 72 | 2023 | 230 | 6.170 |
Why?
|
| Neurofibrillary Tangles | 63 | 2023 | 199 | 6.120 |
Why?
|
| Risk Factors | 161 | 2023 | 2581 | 5.790 |
Why?
|
| Disease Progression | 95 | 2022 | 832 | 5.700 |
Why?
|
| Neurodegenerative Diseases | 20 | 2022 | 119 | 5.570 |
Why?
|
| Motor Activity | 30 | 2021 | 370 | 5.430 |
Why?
|
| DNA Methylation | 27 | 2023 | 132 | 5.380 |
Why?
|
| Cerebral Infarction | 30 | 2023 | 164 | 5.320 |
Why?
|
| Nervous System Diseases | 14 | 2023 | 156 | 5.200 |
Why?
|
| Autopsy | 73 | 2023 | 352 | 5.120 |
Why?
|
| Memory Disorders | 39 | 2020 | 178 | 5.100 |
Why?
|
| Hippocampus | 51 | 2022 | 284 | 5.090 |
Why?
|
| Independent Living | 44 | 2023 | 321 | 5.090 |
Why?
|
| Disabled Persons | 18 | 2023 | 135 | 4.910 |
Why?
|
| Activities of Daily Living | 45 | 2023 | 551 | 4.840 |
Why?
|
| Neurons | 48 | 2022 | 377 | 4.800 |
Why?
|
| Educational Status | 56 | 2023 | 312 | 4.780 |
Why?
|
| Prefrontal Cortex | 24 | 2023 | 151 | 4.670 |
Why?
|
| Plaque, Amyloid | 50 | 2023 | 153 | 4.480 |
Why?
|
| Lewy Bodies | 33 | 2023 | 206 | 4.430 |
Why?
|
| Cerebrovascular Disorders | 23 | 2023 | 149 | 4.380 |
Why?
|
| Cognitive Reserve | 16 | 2022 | 41 | 4.260 |
Why?
|
| Memory, Episodic | 29 | 2023 | 128 | 4.190 |
Why?
|
| Geriatric Assessment | 29 | 2021 | 238 | 4.160 |
Why?
|
| TDP-43 Proteinopathies | 22 | 2023 | 113 | 4.120 |
Why?
|
| Health Literacy | 18 | 2023 | 108 | 4.100 |
Why?
|
| Genotype | 74 | 2023 | 427 | 4.070 |
Why?
|
| Residence Characteristics | 21 | 2021 | 224 | 4.000 |
Why?
|
| Magnetic Resonance Imaging | 67 | 2023 | 1320 | 3.920 |
Why?
|
| Prospective Studies | 84 | 2023 | 1896 | 3.910 |
Why?
|
| Decision Making | 23 | 2023 | 236 | 3.890 |
Why?
|
| Proteomics | 23 | 2023 | 97 | 3.880 |
Why?
|
| Cerebral Cortex | 22 | 2022 | 197 | 3.860 |
Why?
|
| Follow-Up Studies | 85 | 2021 | 1936 | 3.760 |
Why?
|
| Nerve Tissue Proteins | 23 | 2022 | 174 | 3.640 |
Why?
|
| Transcriptome | 27 | 2022 | 88 | 3.570 |
Why?
|
| Parkinson Disease | 34 | 2023 | 1066 | 3.570 |
Why?
|
| Cognitive Aging | 14 | 2021 | 87 | 3.390 |
Why?
|
| Depression | 27 | 2021 | 481 | 3.340 |
Why?
|
| Age Factors | 74 | 2021 | 872 | 3.340 |
Why?
|
| Middle Aged | 176 | 2021 | 10223 | 3.240 |
Why?
|
| Cerebral Amyloid Angiopathy | 18 | 2023 | 120 | 3.190 |
Why?
|
| Proportional Hazards Models | 49 | 2022 | 367 | 3.160 |
Why?
|
| Exercise | 21 | 2023 | 505 | 3.060 |
Why?
|
| Membrane Proteins | 19 | 2022 | 185 | 2.920 |
Why?
|
| Biomarkers | 41 | 2023 | 728 | 2.910 |
Why?
|
| United States | 75 | 2024 | 2376 | 2.900 |
Why?
|
| Epigenesis, Genetic | 18 | 2022 | 76 | 2.850 |
Why?
|
| Synapses | 10 | 2021 | 49 | 2.840 |
Why?
|
| Disability Evaluation | 23 | 2020 | 333 | 2.830 |
Why?
|
| Mobility Limitation | 14 | 2021 | 102 | 2.800 |
Why?
|
| Membrane Transport Proteins | 11 | 2022 | 60 | 2.790 |
Why?
|
| Brain Diseases | 7 | 2021 | 82 | 2.790 |
Why?
|
| Frail Elderly | 9 | 2021 | 52 | 2.780 |
Why?
|
| Muscle Strength | 15 | 2021 | 136 | 2.760 |
Why?
|
| DNA-Binding Proteins | 31 | 2023 | 274 | 2.710 |
Why?
|
| Microglia | 20 | 2023 | 132 | 2.690 |
Why?
|
| Genetic Variation | 24 | 2021 | 112 | 2.660 |
Why?
|
| Loneliness | 10 | 2023 | 61 | 2.660 |
Why?
|
| Olfaction Disorders | 11 | 2021 | 57 | 2.630 |
Why?
|
| Genetic Loci | 21 | 2021 | 65 | 2.620 |
Why?
|
| Lewy Body Disease | 18 | 2021 | 104 | 2.590 |
Why?
|
| White Matter | 16 | 2022 | 157 | 2.540 |
Why?
|
| Neuropathology | 15 | 2023 | 87 | 2.530 |
Why?
|
| Genetic Association Studies | 24 | 2022 | 91 | 2.530 |
Why?
|
| Personality | 9 | 2022 | 68 | 2.450 |
Why?
|
| Incidence | 56 | 2021 | 783 | 2.380 |
Why?
|
| Genome, Human | 9 | 2021 | 50 | 2.290 |
Why?
|
| Sex Characteristics | 19 | 2022 | 144 | 2.250 |
Why?
|
| Psychomotor Performance | 17 | 2021 | 219 | 2.240 |
Why?
|
| Amyloid | 15 | 2022 | 58 | 2.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 15 | 2021 | 80 | 2.200 |
Why?
|
| Brain Mapping | 18 | 2022 | 193 | 2.180 |
Why?
|
| Frontal Lobe | 20 | 2022 | 83 | 2.180 |
Why?
|
| Stress, Psychological | 12 | 2021 | 254 | 2.160 |
Why?
|
| Gene Expression | 16 | 2023 | 239 | 2.130 |
Why?
|
| Risk Assessment | 26 | 2022 | 715 | 2.110 |
Why?
|
| Chicago | 44 | 2021 | 938 | 2.110 |
Why?
|
| Alleles | 34 | 2023 | 236 | 2.100 |
Why?
|
| Arteriolosclerosis | 13 | 2023 | 82 | 2.060 |
Why?
|
| Gray Matter | 7 | 2021 | 59 | 2.060 |
Why?
|
| Social Behavior | 11 | 2021 | 103 | 2.050 |
Why?
|
| Membrane Glycoproteins | 12 | 2021 | 107 | 1.990 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2020 | 213 | 1.970 |
Why?
|
| Proteome | 12 | 2023 | 44 | 1.970 |
Why?
|
| Sex Factors | 37 | 2021 | 508 | 1.960 |
Why?
|
| Multifactorial Inheritance | 13 | 2021 | 24 | 1.950 |
Why?
|
| Comorbidity | 34 | 2021 | 507 | 1.910 |
Why?
|
| Linear Models | 33 | 2023 | 272 | 1.900 |
Why?
|
| Cross-Sectional Studies | 50 | 2023 | 999 | 1.850 |
Why?
|
| Mental Recall | 13 | 2020 | 72 | 1.830 |
Why?
|
| Receptors, Immunologic | 9 | 2021 | 36 | 1.790 |
Why?
|
| Gait | 17 | 2023 | 407 | 1.770 |
Why?
|
| Mortality | 10 | 2021 | 89 | 1.760 |
Why?
|
| Brain Infarction | 13 | 2021 | 74 | 1.730 |
Why?
|
| Risk | 32 | 2020 | 224 | 1.710 |
Why?
|
| Temporal Lobe | 22 | 2021 | 104 | 1.700 |
Why?
|
| Motor Disorders | 4 | 2023 | 25 | 1.690 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 4 | 2019 | 27 | 1.640 |
Why?
|
| Phenotype | 31 | 2023 | 376 | 1.590 |
Why?
|
| Neuroimaging | 13 | 2023 | 144 | 1.580 |
Why?
|
| Gait Disorders, Neurologic | 12 | 2018 | 144 | 1.580 |
Why?
|
| Movement Disorders | 8 | 2021 | 118 | 1.570 |
Why?
|
| Time Factors | 36 | 2021 | 1678 | 1.570 |
Why?
|
| Longevity | 10 | 2022 | 33 | 1.560 |
Why?
|
| Walking Speed | 3 | 2021 | 43 | 1.550 |
Why?
|
| Frontotemporal Lobar Degeneration | 6 | 2022 | 29 | 1.550 |
Why?
|
| Intracranial Arteriosclerosis | 12 | 2022 | 55 | 1.550 |
Why?
|
| Peptides | 7 | 2021 | 97 | 1.530 |
Why?
|
| Quantitative Trait Loci | 20 | 2021 | 61 | 1.520 |
Why?
|
| Psychiatric Status Rating Scales | 24 | 2017 | 356 | 1.510 |
Why?
|
| Hand Strength | 7 | 2023 | 62 | 1.510 |
Why?
|
| Frailty | 6 | 2023 | 39 | 1.490 |
Why?
|
| Neural Pathways | 6 | 2014 | 83 | 1.490 |
Why?
|
| Polymorphism, Genetic | 6 | 2017 | 75 | 1.470 |
Why?
|
| Nerve Degeneration | 12 | 2021 | 54 | 1.470 |
Why?
|
| Nuclear Proteins | 9 | 2021 | 85 | 1.460 |
Why?
|
| Regression Analysis | 24 | 2021 | 301 | 1.450 |
Why?
|
| Animals | 68 | 2023 | 4713 | 1.450 |
Why?
|
| Atherosclerosis | 5 | 2023 | 76 | 1.430 |
Why?
|
| Body Mass Index | 15 | 2023 | 448 | 1.420 |
Why?
|
| Choice Behavior | 4 | 2019 | 56 | 1.410 |
Why?
|
| Diet, Mediterranean | 10 | 2023 | 93 | 1.400 |
Why?
|
| Substantia Nigra | 7 | 2021 | 145 | 1.390 |
Why?
|
| Spinal Cord | 5 | 2022 | 107 | 1.380 |
Why?
|
| Interpersonal Relations | 6 | 2014 | 111 | 1.370 |
Why?
|
| Financial Management | 5 | 2020 | 25 | 1.370 |
Why?
|
| Gene Expression Profiling | 18 | 2023 | 164 | 1.360 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2021 | 36 | 1.320 |
Why?
|
| Life Style | 9 | 2021 | 226 | 1.320 |
Why?
|
| Severity of Illness Index | 36 | 2021 | 1134 | 1.310 |
Why?
|
| Sleep | 13 | 2022 | 321 | 1.300 |
Why?
|
| Stroke | 10 | 2023 | 315 | 1.300 |
Why?
|
| Quality of Life | 6 | 2015 | 697 | 1.290 |
Why?
|
| Delay Discounting | 4 | 2023 | 27 | 1.290 |
Why?
|
| Gene Expression Regulation | 23 | 2021 | 286 | 1.270 |
Why?
|
| RNA, Messenger | 15 | 2022 | 329 | 1.260 |
Why?
|
| Risk-Taking | 5 | 2019 | 33 | 1.240 |
Why?
|
| Neocortex | 8 | 2019 | 34 | 1.220 |
Why?
|
| Motor Skills | 7 | 2021 | 61 | 1.220 |
Why?
|
| Fraud | 4 | 2022 | 24 | 1.210 |
Why?
|
| Music | 2 | 2021 | 21 | 1.200 |
Why?
|
| Cause of Death | 4 | 2021 | 70 | 1.190 |
Why?
|
| Models, Statistical | 10 | 2020 | 135 | 1.180 |
Why?
|
| Death | 5 | 2021 | 53 | 1.180 |
Why?
|
| Muscle Weakness | 5 | 2021 | 34 | 1.180 |
Why?
|
| Mental Health | 5 | 2016 | 113 | 1.170 |
Why?
|
| Blood Pressure | 10 | 2022 | 262 | 1.160 |
Why?
|
| Diabetes Mellitus | 10 | 2023 | 147 | 1.150 |
Why?
|
| Epigenomics | 7 | 2021 | 12 | 1.130 |
Why?
|
| National Institute on Aging (U.S.) | 7 | 2022 | 18 | 1.130 |
Why?
|
| Circadian Rhythm | 9 | 2023 | 294 | 1.130 |
Why?
|
| Haplotypes | 10 | 2021 | 64 | 1.130 |
Why?
|
| Gene Regulatory Networks | 8 | 2020 | 34 | 1.120 |
Why?
|
| Image Processing, Computer-Assisted | 15 | 2023 | 226 | 1.120 |
Why?
|
| Cytomegalovirus Infections | 4 | 2015 | 83 | 1.110 |
Why?
|
| Movement | 4 | 2020 | 137 | 1.110 |
Why?
|
| Cardiovascular Diseases | 8 | 2023 | 422 | 1.100 |
Why?
|
| Entorhinal Cortex | 15 | 2021 | 40 | 1.090 |
Why?
|
| Sarcopenia | 3 | 2021 | 33 | 1.080 |
Why?
|
| SNARE Proteins | 4 | 2021 | 14 | 1.070 |
Why?
|
| Goals | 4 | 2017 | 45 | 1.060 |
Why?
|
| Hemoglobins | 3 | 2012 | 82 | 1.050 |
Why?
|
| Literacy | 3 | 2021 | 17 | 1.040 |
Why?
|
| Family | 4 | 2021 | 100 | 1.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 6 | 2021 | 42 | 1.040 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 55 | 1.040 |
Why?
|
| Anxiety | 4 | 2013 | 156 | 1.030 |
Why?
|
| Locus Coeruleus | 4 | 2021 | 23 | 1.020 |
Why?
|
| Mice | 40 | 2023 | 1681 | 1.000 |
Why?
|
| Anxiety Disorders | 5 | 2016 | 171 | 1.000 |
Why?
|
| Wearable Electronic Devices | 3 | 2020 | 43 | 0.990 |
Why?
|
| Peptide Fragments | 16 | 2022 | 98 | 0.990 |
Why?
|
| Brain Chemistry | 8 | 2021 | 46 | 0.990 |
Why?
|
| Sleep Deprivation | 6 | 2022 | 65 | 0.980 |
Why?
|
| Diet | 11 | 2022 | 194 | 0.980 |
Why?
|
| Proteins | 4 | 2020 | 73 | 0.980 |
Why?
|
| Amyloidosis | 8 | 2022 | 28 | 0.980 |
Why?
|
| Logistic Models | 25 | 2020 | 410 | 0.980 |
Why?
|
| Mice, Transgenic | 29 | 2022 | 260 | 0.980 |
Why?
|
| Case-Control Studies | 31 | 2021 | 661 | 0.960 |
Why?
|
| Histones | 3 | 2019 | 28 | 0.960 |
Why?
|
| Adult | 58 | 2023 | 8944 | 0.950 |
Why?
|
| Economics | 4 | 2019 | 18 | 0.950 |
Why?
|
| Brazil | 5 | 2021 | 46 | 0.950 |
Why?
|
| Hypertension | 11 | 2022 | 288 | 0.950 |
Why?
|
| Psychometrics | 22 | 2017 | 270 | 0.940 |
Why?
|
| Depressive Disorder, Major | 5 | 2017 | 108 | 0.940 |
Why?
|
| alpha-Synuclein | 11 | 2021 | 141 | 0.940 |
Why?
|
| Physical Fitness | 4 | 2016 | 60 | 0.940 |
Why?
|
| Mental Status Schedule | 17 | 2018 | 121 | 0.940 |
Why?
|
| Odorants | 6 | 2021 | 23 | 0.940 |
Why?
|
| Self Report | 11 | 2022 | 231 | 0.940 |
Why?
|
| CpG Islands | 10 | 2021 | 36 | 0.930 |
Why?
|
| Statistics as Topic | 20 | 2017 | 116 | 0.920 |
Why?
|
| Homozygote | 4 | 2020 | 25 | 0.910 |
Why?
|
| Atrophy | 17 | 2021 | 103 | 0.910 |
Why?
|
| Sequence Analysis, RNA | 13 | 2023 | 44 | 0.910 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2020 | 6 | 0.900 |
Why?
|
| Depressive Disorder | 9 | 2019 | 192 | 0.890 |
Why?
|
| Diffusion Tensor Imaging | 8 | 2023 | 86 | 0.890 |
Why?
|
| LDL-Receptor Related Proteins | 6 | 2022 | 17 | 0.880 |
Why?
|
| Antibodies, Antiphospholipid | 3 | 2019 | 26 | 0.880 |
Why?
|
| MicroRNAs | 6 | 2022 | 47 | 0.880 |
Why?
|
| Adaptation, Psychological | 3 | 2020 | 147 | 0.880 |
Why?
|
| HSP27 Heat-Shock Proteins | 3 | 2019 | 19 | 0.870 |
Why?
|
| Research Design | 7 | 2021 | 219 | 0.870 |
Why?
|
| Algorithms | 11 | 2021 | 416 | 0.870 |
Why?
|
| Inflammation | 9 | 2022 | 361 | 0.850 |
Why?
|
| Cerebrum | 1 | 2023 | 13 | 0.850 |
Why?
|
| Dementia, Vascular | 9 | 2018 | 44 | 0.850 |
Why?
|
| Social Environment | 4 | 2021 | 87 | 0.840 |
Why?
|
| Learning | 4 | 2018 | 80 | 0.840 |
Why?
|
| Prevalence | 22 | 2019 | 498 | 0.840 |
Why?
|
| Actigraphy | 17 | 2022 | 99 | 0.840 |
Why?
|
| Nerve Net | 4 | 2019 | 52 | 0.830 |
Why?
|
| Financing, Personal | 5 | 2020 | 20 | 0.820 |
Why?
|
| Clergy | 14 | 2013 | 90 | 0.820 |
Why?
|
| Causality | 11 | 2021 | 54 | 0.810 |
Why?
|
| Attention | 5 | 2009 | 145 | 0.810 |
Why?
|
| Apolipoprotein E3 | 6 | 2022 | 18 | 0.810 |
Why?
|
| Neoplasms | 4 | 2018 | 261 | 0.800 |
Why?
|
| Memory, Short-Term | 10 | 2021 | 104 | 0.800 |
Why?
|
| Visual Perception | 7 | 2017 | 48 | 0.790 |
Why?
|
| Vascular Diseases | 5 | 2021 | 52 | 0.790 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 66 | 0.790 |
Why?
|
| Muscle Rigidity | 7 | 2014 | 26 | 0.790 |
Why?
|
| Memory and Learning Tests | 2 | 2020 | 7 | 0.790 |
Why?
|
| Health Status | 7 | 2019 | 239 | 0.780 |
Why?
|
| Mental Status and Dementia Tests | 7 | 2021 | 89 | 0.780 |
Why?
|
| Postural Balance | 6 | 2018 | 124 | 0.780 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 8 | 0.780 |
Why?
|
| Receptors, IgG | 2 | 2021 | 21 | 0.770 |
Why?
|
| Models, Psychological | 4 | 2015 | 70 | 0.770 |
Why?
|
| Sclerosis | 10 | 2022 | 71 | 0.760 |
Why?
|
| Microvessels | 2 | 2019 | 17 | 0.750 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 115 | 0.750 |
Why?
|
| Motor Neurons | 2 | 2018 | 19 | 0.750 |
Why?
|
| Social Discrimination | 1 | 2021 | 8 | 0.750 |
Why?
|
| Muscle, Skeletal | 6 | 2021 | 370 | 0.740 |
Why?
|
| Emotions | 2 | 2012 | 89 | 0.740 |
Why?
|
| Carrier Proteins | 4 | 2021 | 102 | 0.740 |
Why?
|
| Serial Learning | 1 | 2020 | 8 | 0.740 |
Why?
|
| Galectin 3 | 1 | 2020 | 4 | 0.740 |
Why?
|
| Galectins | 1 | 2020 | 7 | 0.730 |
Why?
|
| Galectin 1 | 1 | 2020 | 4 | 0.730 |
Why?
|
| Astrocytes | 8 | 2022 | 127 | 0.730 |
Why?
|
| RNA | 8 | 2023 | 39 | 0.730 |
Why?
|
| Information Literacy | 3 | 2019 | 10 | 0.730 |
Why?
|
| Immunohistochemistry | 23 | 2021 | 430 | 0.730 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 12 | 0.720 |
Why?
|
| Crime Victims | 2 | 2022 | 25 | 0.720 |
Why?
|
| Parietal Lobe | 6 | 2021 | 21 | 0.710 |
Why?
|
| Transcription Factors | 9 | 2021 | 169 | 0.710 |
Why?
|
| Leg | 4 | 2008 | 51 | 0.700 |
Why?
|
| Genomics | 3 | 2021 | 55 | 0.700 |
Why?
|
| Agnosia | 2 | 2012 | 11 | 0.700 |
Why?
|
| HIV Infections | 4 | 2020 | 886 | 0.700 |
Why?
|
| Intelligence | 2 | 2020 | 26 | 0.700 |
Why?
|
| ATP-Binding Cassette Transporters | 5 | 2016 | 21 | 0.700 |
Why?
|
| Delivery of Health Care | 7 | 2023 | 159 | 0.700 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 44 | 0.700 |
Why?
|
| Child Development | 1 | 2020 | 71 | 0.690 |
Why?
|
| Drug Discovery | 2 | 2017 | 21 | 0.680 |
Why?
|
| Awareness | 2 | 2019 | 41 | 0.680 |
Why?
|
| Language | 5 | 2018 | 79 | 0.680 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 7 | 0.680 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 14 | 0.670 |
Why?
|
| Child Abuse | 2 | 2012 | 38 | 0.670 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2009 | 105 | 0.670 |
Why?
|
| Disease Models, Animal | 20 | 2022 | 782 | 0.670 |
Why?
|
| Neurologic Examination | 13 | 2020 | 138 | 0.670 |
Why?
|
| Metabolomics | 6 | 2021 | 23 | 0.660 |
Why?
|
| Caspase 6 | 7 | 2016 | 7 | 0.660 |
Why?
|
| Bayes Theorem | 7 | 2021 | 41 | 0.660 |
Why?
|
| Physicians | 2 | 2020 | 119 | 0.650 |
Why?
|
| Reward | 3 | 2019 | 34 | 0.650 |
Why?
|
| Socioeconomic Factors | 12 | 2020 | 333 | 0.650 |
Why?
|
| Neuroticism | 9 | 2022 | 37 | 0.650 |
Why?
|
| Age of Onset | 14 | 2022 | 109 | 0.640 |
Why?
|
| Models, Neurological | 3 | 2016 | 30 | 0.630 |
Why?
|
| Brain Injuries, Traumatic | 4 | 2022 | 29 | 0.630 |
Why?
|
| Endophenotypes | 5 | 2015 | 12 | 0.630 |
Why?
|
| Reading | 9 | 2021 | 46 | 0.630 |
Why?
|
| Epidemiologic Studies | 5 | 2012 | 24 | 0.630 |
Why?
|
| Odds Ratio | 17 | 2018 | 293 | 0.620 |
Why?
|
| Kidney | 2 | 2010 | 181 | 0.620 |
Why?
|
| Comprehension | 3 | 2016 | 29 | 0.610 |
Why?
|
| Qa-SNARE Proteins | 2 | 2021 | 7 | 0.610 |
Why?
|
| Pain | 3 | 2023 | 426 | 0.610 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 4 | 2021 | 42 | 0.610 |
Why?
|
| Lung | 2 | 2009 | 173 | 0.610 |
Why?
|
| Interviews as Topic | 4 | 2021 | 132 | 0.610 |
Why?
|
| Ankyrins | 2 | 2014 | 4 | 0.600 |
Why?
|
| Psychological Tests | 7 | 2015 | 50 | 0.600 |
Why?
|
| Perception | 5 | 2021 | 85 | 0.600 |
Why?
|
| Prognosis | 13 | 2020 | 923 | 0.590 |
Why?
|
| Tauopathies | 5 | 2023 | 20 | 0.590 |
Why?
|
| Neuropeptides | 4 | 2023 | 31 | 0.590 |
Why?
|
| Diagnosis, Differential | 8 | 2011 | 408 | 0.590 |
Why?
|
| Dietary Approaches To Stop Hypertension | 3 | 2023 | 31 | 0.570 |
Why?
|
| Drosophila melanogaster | 5 | 2019 | 18 | 0.570 |
Why?
|
| Brain Stem | 2 | 2016 | 25 | 0.560 |
Why?
|
| Personal Satisfaction | 2 | 2016 | 49 | 0.560 |
Why?
|
| Executive Function | 8 | 2023 | 125 | 0.560 |
Why?
|
| Nucleus Accumbens | 1 | 2016 | 25 | 0.550 |
Why?
|
| Predictive Value of Tests | 15 | 2016 | 555 | 0.550 |
Why?
|
| Microfilament Proteins | 4 | 2019 | 23 | 0.550 |
Why?
|
| Hospitalization | 5 | 2019 | 336 | 0.550 |
Why?
|
| Reaction Time | 10 | 2021 | 128 | 0.550 |
Why?
|
| Metabolome | 4 | 2020 | 16 | 0.550 |
Why?
|
| Positron-Emission Tomography | 9 | 2023 | 98 | 0.540 |
Why?
|
| Receptors, Complement 3b | 6 | 2016 | 16 | 0.540 |
Why?
|
| Income | 7 | 2023 | 78 | 0.540 |
Why?
|
| Amyloid beta-Protein Precursor | 8 | 2022 | 22 | 0.540 |
Why?
|
| Life | 2 | 2006 | 9 | 0.530 |
Why?
|
| Apolipoprotein E2 | 5 | 2023 | 14 | 0.530 |
Why?
|
| Cerebellum | 5 | 2016 | 53 | 0.530 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 51 | 0.520 |
Why?
|
| Olfactory Bulb | 3 | 2023 | 19 | 0.520 |
Why?
|
| Intention | 3 | 2010 | 28 | 0.520 |
Why?
|
| Population Surveillance | 2 | 2017 | 123 | 0.520 |
Why?
|
| Child | 14 | 2020 | 1428 | 0.520 |
Why?
|
| Tissue Donors | 4 | 2020 | 81 | 0.510 |
Why?
|
| Chronic Disease | 7 | 2017 | 534 | 0.510 |
Why?
|
| Signal Transduction | 14 | 2021 | 498 | 0.510 |
Why?
|
| Gene Frequency | 14 | 2018 | 73 | 0.510 |
Why?
|
| Body Composition | 3 | 2019 | 62 | 0.510 |
Why?
|
| Diabetes Complications | 8 | 2021 | 68 | 0.510 |
Why?
|
| Reference Values | 9 | 2020 | 231 | 0.500 |
Why?
|
| Survival Rate | 3 | 2012 | 407 | 0.500 |
Why?
|
| Association | 2 | 2012 | 9 | 0.500 |
Why?
|
| Trust | 2 | 2019 | 17 | 0.500 |
Why?
|
| Mutation | 9 | 2022 | 405 | 0.500 |
Why?
|
| Antiporters | 1 | 2015 | 6 | 0.490 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 6 | 0.490 |
Why?
|
| Data Interpretation, Statistical | 13 | 2022 | 100 | 0.490 |
Why?
|
| Sleep Wake Disorders | 5 | 2019 | 149 | 0.490 |
Why?
|
| Exercise Test | 1 | 2016 | 129 | 0.490 |
Why?
|
| Illinois | 8 | 2020 | 266 | 0.490 |
Why?
|
| Prodromal Symptoms | 4 | 2020 | 19 | 0.490 |
Why?
|
| Reproducibility of Results | 18 | 2022 | 820 | 0.490 |
Why?
|
| Postmortem Changes | 9 | 2019 | 34 | 0.490 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 7 | 2017 | 17 | 0.480 |
Why?
|
| Seafood | 4 | 2018 | 10 | 0.480 |
Why?
|
| Neurotic Disorders | 4 | 2011 | 20 | 0.480 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 224 | 0.480 |
Why?
|
| Social Isolation | 4 | 2023 | 27 | 0.480 |
Why?
|
| Heterozygote | 8 | 2021 | 108 | 0.480 |
Why?
|
| Multilingualism | 1 | 2014 | 11 | 0.470 |
Why?
|
| Harm Reduction | 1 | 2014 | 5 | 0.470 |
Why?
|
| Respiratory Muscles | 3 | 2008 | 19 | 0.470 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 19 | 0.470 |
Why?
|
| CLOCK Proteins | 2 | 2017 | 28 | 0.470 |
Why?
|
| Poverty | 1 | 2015 | 97 | 0.470 |
Why?
|
| Disease Susceptibility | 7 | 2019 | 85 | 0.470 |
Why?
|
| Smell | 3 | 2021 | 19 | 0.460 |
Why?
|
| Health Behavior | 5 | 2021 | 163 | 0.460 |
Why?
|
| Locomotion | 1 | 2014 | 25 | 0.460 |
Why?
|
| Verbal Learning | 5 | 2014 | 39 | 0.450 |
Why?
|
| Mesencephalon | 1 | 2013 | 44 | 0.450 |
Why?
|
| Bile Acids and Salts | 4 | 2021 | 11 | 0.450 |
Why?
|
| Acculturation | 3 | 2023 | 40 | 0.450 |
Why?
|
| Mental Disorders | 5 | 2021 | 145 | 0.440 |
Why?
|
| Organ Size | 10 | 2019 | 108 | 0.440 |
Why?
|
| Social Support | 4 | 2020 | 194 | 0.440 |
Why?
|
| Dyssomnias | 1 | 2013 | 8 | 0.440 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 28 | 0.440 |
Why?
|
| Survival Analysis | 11 | 2019 | 322 | 0.440 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 10 | 0.430 |
Why?
|
| Automobile Driving | 2 | 2012 | 12 | 0.430 |
Why?
|
| Immunotherapy | 2 | 2021 | 68 | 0.430 |
Why?
|
| Consensus | 1 | 2013 | 112 | 0.430 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 70 | 0.430 |
Why?
|
| Vision Disorders | 1 | 2012 | 23 | 0.430 |
Why?
|
| Self Stimulation | 2 | 2003 | 12 | 0.430 |
Why?
|
| RNA Splicing | 4 | 2019 | 11 | 0.420 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 21 | 0.420 |
Why?
|
| Insulin | 5 | 2021 | 97 | 0.420 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2011 | 5 | 0.420 |
Why?
|
| Anisotropy | 6 | 2023 | 62 | 0.420 |
Why?
|
| Parkinson Disease, Secondary | 3 | 2005 | 20 | 0.420 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2012 | 3 | 0.410 |
Why?
|
| Data Collection | 3 | 2010 | 109 | 0.410 |
Why?
|
| Databases, Factual | 3 | 2020 | 353 | 0.410 |
Why?
|
| Terminally Ill | 1 | 2012 | 5 | 0.410 |
Why?
|
| Induced Pluripotent Stem Cells | 4 | 2021 | 20 | 0.410 |
Why?
|
| Cytoskeletal Proteins | 4 | 2019 | 25 | 0.410 |
Why?
|
| Accelerometry | 4 | 2020 | 94 | 0.410 |
Why?
|
| Social Class | 5 | 2022 | 68 | 0.410 |
Why?
|
| Limbic Encephalitis | 2 | 2023 | 12 | 0.400 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 10 | 0.400 |
Why?
|
| Synaptotagmins | 2 | 2021 | 5 | 0.400 |
Why?
|
| Social Adjustment | 2 | 2009 | 31 | 0.400 |
Why?
|
| Surveys and Questionnaires | 12 | 2021 | 1210 | 0.400 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 128 | 0.400 |
Why?
|
| Confidence Intervals | 9 | 2012 | 97 | 0.390 |
Why?
|
| Fatigue | 2 | 2009 | 65 | 0.390 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 42 | 0.390 |
Why?
|
| Amygdala | 3 | 2021 | 50 | 0.390 |
Why?
|
| September 11 Terrorist Attacks | 2 | 2021 | 11 | 0.390 |
Why?
|
| Self-Assessment | 3 | 2021 | 32 | 0.390 |
Why?
|
| Medicare | 5 | 2024 | 127 | 0.390 |
Why?
|
| Young Adult | 15 | 2020 | 2057 | 0.390 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2021 | 199 | 0.380 |
Why?
|
| Community Health Services | 2 | 2009 | 31 | 0.380 |
Why?
|
| Housing for the Elderly | 2 | 2010 | 8 | 0.380 |
Why?
|
| Chronic Pain | 1 | 2012 | 111 | 0.380 |
Why?
|
| Genetic Testing | 7 | 2019 | 65 | 0.380 |
Why?
|
| Schizophrenia | 5 | 2018 | 80 | 0.380 |
Why?
|
| Urban Population | 11 | 2011 | 148 | 0.380 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2021 | 12 | 0.370 |
Why?
|
| Sex Distribution | 6 | 2014 | 89 | 0.370 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2022 | 105 | 0.370 |
Why?
|
| Social Participation | 1 | 2011 | 12 | 0.370 |
Why?
|
| Population Groups | 2 | 2021 | 6 | 0.370 |
Why?
|
| Psychology | 3 | 2021 | 24 | 0.370 |
Why?
|
| Drosophila Proteins | 3 | 2019 | 11 | 0.370 |
Why?
|
| Environmental Health | 1 | 2010 | 10 | 0.370 |
Why?
|
| RNA Splicing Factors | 2 | 2020 | 5 | 0.370 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.370 |
Why?
|
| Statistics, Nonparametric | 7 | 2015 | 143 | 0.370 |
Why?
|
| Hypokinesia | 5 | 2014 | 28 | 0.370 |
Why?
|
| Knowledge | 1 | 2010 | 19 | 0.360 |
Why?
|
| Mitochondria | 5 | 2021 | 86 | 0.360 |
Why?
|
| Fatty Acids | 5 | 2022 | 41 | 0.360 |
Why?
|
| Pericytes | 2 | 2020 | 5 | 0.360 |
Why?
|
| Walking | 6 | 2023 | 258 | 0.360 |
Why?
|
| Models, Biological | 7 | 2019 | 346 | 0.360 |
Why?
|
| Molecular Chaperones | 3 | 2020 | 13 | 0.360 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2021 | 8 | 0.360 |
Why?
|
| Phobic Disorders | 1 | 2010 | 66 | 0.360 |
Why?
|
| Affect | 2 | 2016 | 66 | 0.350 |
Why?
|
| Potassium | 1 | 2010 | 68 | 0.350 |
Why?
|
| Reactive Oxygen Species | 6 | 2022 | 132 | 0.350 |
Why?
|
| Computational Biology | 6 | 2020 | 24 | 0.350 |
Why?
|
| Synapsins | 2 | 2021 | 6 | 0.350 |
Why?
|
| Oxidative Stress | 7 | 2022 | 134 | 0.340 |
Why?
|
| Blood Glucose | 2 | 2022 | 120 | 0.340 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 81 | 0.340 |
Why?
|
| Community Health Planning | 3 | 2018 | 23 | 0.340 |
Why?
|
| Protein Interaction Maps | 4 | 2018 | 18 | 0.340 |
Why?
|
| Analysis of Variance | 9 | 2021 | 326 | 0.340 |
Why?
|
| Proteostasis | 2 | 2019 | 4 | 0.340 |
Why?
|
| Somatosensory Disorders | 1 | 2009 | 10 | 0.330 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 24 | 0.330 |
Why?
|
| Phosphorylation | 11 | 2021 | 163 | 0.330 |
Why?
|
| Cell Count | 8 | 2015 | 98 | 0.330 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 55 | 0.330 |
Why?
|
| Vibration | 1 | 2009 | 26 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 58 | 0.330 |
Why?
|
| Leisure Activities | 2 | 2006 | 12 | 0.330 |
Why?
|
| Adolescent | 14 | 2020 | 2400 | 0.330 |
Why?
|
| Catholicism | 6 | 2013 | 21 | 0.320 |
Why?
|
| Energy Metabolism | 4 | 2020 | 53 | 0.320 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2019 | 20 | 0.320 |
Why?
|
| Presenilin-1 | 4 | 2021 | 7 | 0.320 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 586 | 0.320 |
Why?
|
| Repressor Proteins | 3 | 2019 | 30 | 0.310 |
Why?
|
| Transcription, Genetic | 6 | 2020 | 107 | 0.310 |
Why?
|
| Accidental Falls | 1 | 2010 | 113 | 0.310 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2021 | 36 | 0.310 |
Why?
|
| Tremor | 7 | 2014 | 141 | 0.310 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2016 | 18 | 0.310 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 4 | 0.310 |
Why?
|
| Neuroimmunomodulation | 1 | 2008 | 10 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 15 | 0.300 |
Why?
|
| Rest | 4 | 2023 | 32 | 0.300 |
Why?
|
| Clusterin | 4 | 2012 | 4 | 0.300 |
Why?
|
| Body Size | 2 | 2019 | 12 | 0.300 |
Why?
|
| Seasons | 2 | 2018 | 32 | 0.300 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 48 | 0.300 |
Why?
|
| Urinary Incontinence | 3 | 2017 | 24 | 0.300 |
Why?
|
| Phospholipases A2, Cytosolic | 3 | 2022 | 6 | 0.300 |
Why?
|
| Age Distribution | 7 | 2014 | 95 | 0.300 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 101 | 0.300 |
Why?
|
| Metabolic Networks and Pathways | 4 | 2021 | 14 | 0.300 |
Why?
|
| Isometric Contraction | 1 | 2007 | 16 | 0.290 |
Why?
|
| Diagnosis | 5 | 2019 | 26 | 0.290 |
Why?
|
| DNA, Mitochondrial | 3 | 2021 | 9 | 0.290 |
Why?
|
| Smoking | 6 | 2020 | 197 | 0.290 |
Why?
|
| Nerve Growth Factor | 4 | 2020 | 33 | 0.290 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 25 | 0.290 |
Why?
|
| GPI-Linked Proteins | 3 | 2023 | 27 | 0.290 |
Why?
|
| Hormone Replacement Therapy | 2 | 2020 | 32 | 0.290 |
Why?
|
| Lower Extremity | 1 | 2007 | 40 | 0.290 |
Why?
|
| Space Perception | 3 | 2019 | 26 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2023 | 75 | 0.290 |
Why?
|
| Epoxide Hydrolases | 3 | 2022 | 10 | 0.290 |
Why?
|
| Personal Space | 1 | 2007 | 7 | 0.280 |
Why?
|
| Personality Disorders | 2 | 2006 | 20 | 0.280 |
Why?
|
| Insulin Resistance | 2 | 2021 | 59 | 0.280 |
Why?
|
| Linkage Disequilibrium | 9 | 2021 | 46 | 0.280 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 80 | 0.280 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2021 | 17 | 0.280 |
Why?
|
| Dyskinesias | 1 | 2006 | 34 | 0.270 |
Why?
|
| Factor Analysis, Statistical | 7 | 2015 | 79 | 0.270 |
Why?
|
| Mitochondrial Proteins | 3 | 2021 | 21 | 0.270 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 52 | 0.270 |
Why?
|
| Infarction | 4 | 2023 | 32 | 0.270 |
Why?
|
| Ischemic Attack, Transient | 1 | 2006 | 21 | 0.270 |
Why?
|
| Chromosome Mapping | 4 | 2019 | 53 | 0.270 |
Why?
|
| Television | 1 | 2006 | 6 | 0.270 |
Why?
|
| Down-Regulation | 6 | 2015 | 114 | 0.270 |
Why?
|
| Probability | 6 | 2021 | 99 | 0.270 |
Why?
|
| Drosophila | 2 | 2019 | 8 | 0.270 |
Why?
|
| Up-Regulation | 5 | 2021 | 177 | 0.270 |
Why?
|
| Nerve Growth Factors | 2 | 2023 | 49 | 0.270 |
Why?
|
| ROC Curve | 4 | 2022 | 145 | 0.260 |
Why?
|
| Heme Oxygenase-1 | 3 | 2014 | 7 | 0.260 |
Why?
|
| Exercise Therapy | 1 | 2007 | 113 | 0.260 |
Why?
|
| Extracellular Matrix Proteins | 4 | 2019 | 131 | 0.260 |
Why?
|
| Single-Cell Analysis | 3 | 2021 | 6 | 0.260 |
Why?
|
| Alternative Splicing | 4 | 2018 | 24 | 0.260 |
Why?
|
| Functional Laterality | 3 | 2008 | 89 | 0.260 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 99 | 0.260 |
Why?
|
| Antioxidants | 3 | 2020 | 65 | 0.260 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 5 | 2012 | 7 | 0.260 |
Why?
|
| Cachexia | 1 | 2005 | 14 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2017 | 72 | 0.260 |
Why?
|
| Demography | 6 | 2018 | 81 | 0.260 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 33 | 0.250 |
Why?
|
| Renal Dialysis | 1 | 2006 | 111 | 0.250 |
Why?
|
| Amnesia | 2 | 2021 | 29 | 0.250 |
Why?
|
| Infant | 4 | 2023 | 571 | 0.250 |
Why?
|
| Psychotic Disorders | 4 | 2017 | 47 | 0.250 |
Why?
|
| Microtubule-Associated Proteins | 5 | 2021 | 21 | 0.250 |
Why?
|
| ARNTL Transcription Factors | 2 | 2016 | 10 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2019 | 134 | 0.250 |
Why?
|
| Blotting, Western | 11 | 2017 | 178 | 0.250 |
Why?
|
| Aspartic Acid Endopeptidases | 4 | 2021 | 9 | 0.250 |
Why?
|
| Heart Diseases | 2 | 2016 | 77 | 0.250 |
Why?
|
| Complement C4 | 2 | 2022 | 4 | 0.250 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2004 | 3 | 0.250 |
Why?
|
| Synaptic Membranes | 1 | 2004 | 3 | 0.250 |
Why?
|
| Receptors, Muscarinic | 1 | 2004 | 6 | 0.250 |
Why?
|
| Cell Nucleus | 4 | 2020 | 80 | 0.250 |
Why?
|
| Chromatin | 2 | 2016 | 15 | 0.240 |
Why?
|
| Diabetic Neuropathies | 1 | 2004 | 14 | 0.240 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 28 | 0.240 |
Why?
|
| Antihypertensive Agents | 4 | 2020 | 88 | 0.240 |
Why?
|
| Personality Inventory | 4 | 2022 | 75 | 0.240 |
Why?
|
| Amyloid Precursor Protein Secretases | 5 | 2022 | 17 | 0.240 |
Why?
|
| Epistasis, Genetic | 3 | 2021 | 9 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 160 | 0.240 |
Why?
|
| Genome | 2 | 2016 | 15 | 0.240 |
Why?
|
| Cells, Cultured | 8 | 2021 | 686 | 0.230 |
Why?
|
| Neprilysin | 3 | 2019 | 10 | 0.230 |
Why?
|
| Family Health | 2 | 2017 | 37 | 0.230 |
Why?
|
| Clinical Trials as Topic | 7 | 2014 | 331 | 0.230 |
Why?
|
| Vesicular Transport Proteins | 2 | 2020 | 9 | 0.230 |
Why?
|
| Cerebral Arteries | 3 | 2016 | 32 | 0.230 |
Why?
|
| Multiple Sclerosis | 2 | 2022 | 84 | 0.230 |
Why?
|
| Retrospective Studies | 7 | 2021 | 3663 | 0.230 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 19 | 0.230 |
Why?
|
| Primary Prevention | 2 | 2019 | 41 | 0.230 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 32 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 21 | 0.230 |
Why?
|
| Government | 1 | 2023 | 3 | 0.220 |
Why?
|
| Choline O-Acetyltransferase | 5 | 2005 | 16 | 0.220 |
Why?
|
| Anthocyanins | 2 | 2022 | 11 | 0.220 |
Why?
|
| Synaptophysin | 2 | 2021 | 9 | 0.220 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2018 | 19 | 0.220 |
Why?
|
| Protein Isoforms | 5 | 2020 | 55 | 0.220 |
Why?
|
| Public Health | 2 | 2001 | 66 | 0.220 |
Why?
|
| Benchmarking | 1 | 2023 | 46 | 0.220 |
Why?
|
| Anger | 1 | 2003 | 31 | 0.220 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 23 | 0.220 |
Why?
|
| Metformin | 1 | 2023 | 24 | 0.220 |
Why?
|
| Inclusion Bodies | 3 | 2014 | 14 | 0.220 |
Why?
|
| Range of Motion, Articular | 2 | 2019 | 737 | 0.220 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 6 | 0.220 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 6 | 0.220 |
Why?
|
| Gene-Environment Interaction | 4 | 2020 | 20 | 0.220 |
Why?
|
| Calcium | 3 | 2022 | 503 | 0.220 |
Why?
|
| Aniline Compounds | 5 | 2017 | 46 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 464 | 0.220 |
Why?
|
| Insulins | 1 | 2022 | 4 | 0.210 |
Why?
|
| Nociceptors | 1 | 2023 | 27 | 0.210 |
Why?
|
| Acetylation | 2 | 2019 | 12 | 0.210 |
Why?
|
| Heart Failure | 2 | 2021 | 223 | 0.210 |
Why?
|
| Period Circadian Proteins | 2 | 2013 | 25 | 0.210 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2002 | 7 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 14 | 0.210 |
Why?
|
| Hallucinations | 4 | 2005 | 69 | 0.210 |
Why?
|
| Exonucleases | 1 | 2022 | 2 | 0.210 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 44 | 0.210 |
Why?
|
| Glycopeptides | 1 | 2022 | 5 | 0.210 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2022 | 4 | 0.210 |
Why?
|
| Retirement | 3 | 2011 | 12 | 0.210 |
Why?
|
| Prenatal Care | 2 | 2020 | 9 | 0.210 |
Why?
|
| Protein Kinases | 2 | 2021 | 15 | 0.210 |
Why?
|
| Posture | 3 | 2014 | 72 | 0.210 |
Why?
|
| Neural Stem Cells | 2 | 2019 | 14 | 0.210 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2022 | 2 | 0.210 |
Why?
|
| Forecasting | 4 | 2014 | 115 | 0.210 |
Why?
|
| Glycation End Products, Advanced | 1 | 2022 | 7 | 0.200 |
Why?
|
| Stem Cells | 1 | 2022 | 49 | 0.200 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2019 | 4 | 0.200 |
Why?
|
| Radar | 1 | 2022 | 7 | 0.200 |
Why?
|
| United Kingdom | 5 | 2021 | 53 | 0.200 |
Why?
|
| ORAI2 Protein | 1 | 2021 | 1 | 0.200 |
Why?
|
| RNA Editing | 1 | 2021 | 1 | 0.200 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 149 | 0.200 |
Why?
|
| Platelet Activation | 1 | 2021 | 4 | 0.200 |
Why?
|
| Child, Preschool | 5 | 2022 | 686 | 0.200 |
Why?
|
| Individuality | 3 | 2022 | 23 | 0.200 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 8 | 0.200 |
Why?
|
| Vitamin A | 1 | 2021 | 6 | 0.200 |
Why?
|
| Megakaryocytes | 1 | 2021 | 27 | 0.200 |
Why?
|
| Verbal Behavior | 2 | 2016 | 20 | 0.200 |
Why?
|
| Metacognition | 1 | 2021 | 3 | 0.200 |
Why?
|
| Synaptosomes | 5 | 2022 | 8 | 0.200 |
Why?
|
| Chromosomes, Human, X | 1 | 2021 | 10 | 0.200 |
Why?
|
| Protein Prenylation | 1 | 2021 | 1 | 0.200 |
Why?
|
| Farnesyltranstransferase | 1 | 2021 | 1 | 0.200 |
Why?
|
| History, 19th Century | 1 | 2021 | 38 | 0.200 |
Why?
|
| Judgment | 2 | 2012 | 9 | 0.200 |
Why?
|
| Protein Biosynthesis | 2 | 2022 | 27 | 0.200 |
Why?
|
| Device Approval | 1 | 2021 | 15 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2019 | 22 | 0.190 |
Why?
|
| Elder Abuse | 1 | 2022 | 35 | 0.190 |
Why?
|
| Netrins | 1 | 2021 | 2 | 0.190 |
Why?
|
| Rats | 8 | 2021 | 870 | 0.190 |
Why?
|
| Anemia | 2 | 2014 | 100 | 0.190 |
Why?
|
| Homeodomain Proteins | 2 | 2020 | 58 | 0.190 |
Why?
|
| History, 20th Century | 1 | 2021 | 70 | 0.190 |
Why?
|
| Ion Mobility Spectrometry | 1 | 2021 | 1 | 0.190 |
Why?
|
| Phospholipase D | 1 | 2021 | 5 | 0.190 |
Why?
|
| beta-Lactamases | 1 | 2021 | 76 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 20 | 0.190 |
Why?
|
| Vitamin E | 4 | 2020 | 29 | 0.190 |
Why?
|
| Environmental Pollutants | 1 | 2021 | 2 | 0.190 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2021 | 6 | 0.190 |
Why?
|
| Oxygen | 2 | 2011 | 87 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 38 | 0.190 |
Why?
|
| Mathematics | 1 | 2021 | 33 | 0.190 |
Why?
|
| Religious Personnel | 2 | 2018 | 12 | 0.190 |
Why?
|
| Axons | 3 | 2020 | 37 | 0.190 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 5 | 0.190 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.190 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2020 | 11 | 0.190 |
Why?
|
| Writing | 1 | 2021 | 22 | 0.180 |
Why?
|
| Apolipoprotein C-I | 1 | 2020 | 2 | 0.180 |
Why?
|
| Ribonucleases | 1 | 2020 | 9 | 0.180 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 82 | 0.180 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 6 | 0.180 |
Why?
|
| Chronobiology Disorders | 1 | 2020 | 14 | 0.180 |
Why?
|
| CREB-Binding Protein | 2 | 2020 | 4 | 0.180 |
Why?
|
| Sexual Partners | 1 | 2020 | 9 | 0.180 |
Why?
|
| Muscle Proteins | 2 | 2018 | 32 | 0.180 |
Why?
|
| Healthy Aging | 1 | 2020 | 16 | 0.180 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 28 | 0.180 |
Why?
|
| Pituitary Hormones | 1 | 2020 | 1 | 0.180 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 2 | 2017 | 4 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 9 | 0.180 |
Why?
|
| Neuronal Plasticity | 5 | 2019 | 44 | 0.180 |
Why?
|
| Mass Spectrometry | 5 | 2022 | 43 | 0.180 |
Why?
|
| Knee Joint | 2 | 2019 | 827 | 0.180 |
Why?
|
| Counseling | 1 | 2020 | 49 | 0.180 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 15 | 0.180 |
Why?
|
| RNA-Binding Proteins | 3 | 2019 | 24 | 0.180 |
Why?
|
| Education | 5 | 2006 | 41 | 0.180 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 18 | 0.180 |
Why?
|
| Genotyping Techniques | 2 | 2017 | 12 | 0.180 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2020 | 5 | 0.180 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 21 | 0.180 |
Why?
|
| Herpesvirus 6, Human | 1 | 2020 | 4 | 0.180 |
Why?
|
| Blood | 1 | 2020 | 25 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 38 | 0.180 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 44 | 0.170 |
Why?
|
| Organ Specificity | 5 | 2020 | 49 | 0.170 |
Why?
|
| Fragaria | 1 | 2019 | 3 | 0.170 |
Why?
|
| Dendritic Spines | 2 | 2017 | 12 | 0.170 |
Why?
|
| Inbreeding Depression | 1 | 2019 | 2 | 0.170 |
Why?
|
| Perceptual Disorders | 2 | 2012 | 7 | 0.170 |
Why?
|
| Consanguinity | 1 | 2019 | 5 | 0.170 |
Why?
|
| Spliceosomes | 1 | 2019 | 1 | 0.170 |
Why?
|
| Flavonols | 1 | 2020 | 12 | 0.170 |
Why?
|
| Fertility | 1 | 2019 | 19 | 0.170 |
Why?
|
| Health Equity | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2019 | 15 | 0.170 |
Why?
|
| Health Surveys | 4 | 2013 | 99 | 0.170 |
Why?
|
| Memantine | 1 | 2019 | 12 | 0.170 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 23 | 0.170 |
Why?
|
| 14-3-3 Proteins | 1 | 2019 | 4 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 214 | 0.170 |
Why?
|
| Occipital Lobe | 1 | 2019 | 11 | 0.170 |
Why?
|
| Adipokines | 1 | 2019 | 8 | 0.170 |
Why?
|
| Sex Chromosomes | 1 | 2019 | 4 | 0.170 |
Why?
|
| Mosaicism | 1 | 2019 | 9 | 0.170 |
Why?
|
| Problem Solving | 1 | 2020 | 47 | 0.170 |
Why?
|
| Spatial Behavior | 2 | 2012 | 13 | 0.170 |
Why?
|
| Amyloidogenic Proteins | 2 | 2017 | 3 | 0.170 |
Why?
|
| Ethylene Glycols | 3 | 2017 | 11 | 0.170 |
Why?
|
| Dinucleoside Phosphates | 1 | 2019 | 1 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 19 | 0.170 |
Why?
|
| Hip Fractures | 1 | 2019 | 34 | 0.170 |
Why?
|
| Glycoproteins | 4 | 2020 | 59 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2017 | 3807 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2020 | 94 | 0.170 |
Why?
|
| Mucin-1 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Monocytes | 3 | 2017 | 115 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2019 | 50 | 0.170 |
Why?
|
| Ubiquitin | 3 | 2010 | 26 | 0.170 |
Why?
|
| Cytokines | 1 | 2021 | 351 | 0.170 |
Why?
|
| Databases, Genetic | 4 | 2021 | 11 | 0.160 |
Why?
|
| Body Fluid Compartments | 1 | 2019 | 5 | 0.160 |
Why?
|
| Markov Chains | 2 | 2018 | 29 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 26 | 0.160 |
Why?
|
| Tuberous Sclerosis | 2 | 2017 | 15 | 0.160 |
Why?
|
| Down Syndrome | 1 | 2019 | 10 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 19 | 0.160 |
Why?
|
| Lipids | 1 | 2019 | 38 | 0.160 |
Why?
|
| Essential Tremor | 1 | 2019 | 15 | 0.160 |
Why?
|
| Indoles | 1 | 2019 | 50 | 0.160 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2015 | 12 | 0.160 |
Why?
|
| Cues | 2 | 2012 | 60 | 0.160 |
Why?
|
| Genetic Linkage | 2 | 2017 | 67 | 0.160 |
Why?
|
| Lateral Ventricles | 1 | 2018 | 7 | 0.160 |
Why?
|
| Calpain | 1 | 2018 | 2 | 0.160 |
Why?
|
| Trinucleotide Repeat Expansion | 2 | 2020 | 46 | 0.160 |
Why?
|
| Emergencies | 1 | 2019 | 41 | 0.160 |
Why?
|
| E2F Transcription Factors | 1 | 2018 | 5 | 0.160 |
Why?
|
| Claudins | 1 | 2018 | 6 | 0.160 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 2015 | 15 | 0.160 |
Why?
|
| Serpins | 1 | 2018 | 5 | 0.160 |
Why?
|
| DNA Transposable Elements | 1 | 2018 | 2 | 0.160 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2009 | 18 | 0.160 |
Why?
|
| Alcoholism | 1 | 2019 | 85 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 16 | 0.160 |
Why?
|
| Parents | 2 | 2012 | 110 | 0.160 |
Why?
|
| Estradiol | 1 | 2018 | 46 | 0.160 |
Why?
|
| Fishes | 1 | 2018 | 4 | 0.160 |
Why?
|
| Osteoarthritis | 1 | 2023 | 384 | 0.160 |
Why?
|
| Task Performance and Analysis | 2 | 2016 | 53 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2019 | 78 | 0.160 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 35 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2016 | 101 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 40 | 0.150 |
Why?
|
| Boston | 6 | 2021 | 28 | 0.150 |
Why?
|
| Epidemiology | 1 | 2018 | 5 | 0.150 |
Why?
|
| Iodide Peroxidase | 1 | 2018 | 34 | 0.150 |
Why?
|
| Phytochemicals | 1 | 2017 | 4 | 0.150 |
Why?
|
| Plant Leaves | 1 | 2017 | 4 | 0.150 |
Why?
|
| Population Health | 1 | 2018 | 5 | 0.150 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2017 | 10 | 0.150 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 13 | 0.150 |
Why?
|
| Vegetables | 1 | 2017 | 20 | 0.150 |
Why?
|
| Glucosylceramidase | 2 | 2021 | 26 | 0.150 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2020 | 117 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2018 | 29 | 0.150 |
Why?
|
| Homocysteine | 1 | 2017 | 8 | 0.150 |
Why?
|
| Enzyme Activation | 6 | 2021 | 113 | 0.150 |
Why?
|
| Personality Assessment | 3 | 2006 | 41 | 0.150 |
Why?
|
| Neurosciences | 1 | 2018 | 11 | 0.150 |
Why?
|
| Transglutaminases | 2 | 2015 | 4 | 0.150 |
Why?
|
| Religion and Psychology | 2 | 2010 | 25 | 0.150 |
Why?
|
| GTP-Binding Proteins | 2 | 2015 | 11 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 100 | 0.150 |
Why?
|
| Actins | 1 | 2017 | 46 | 0.150 |
Why?
|
| Pseudogenes | 1 | 2017 | 2 | 0.150 |
Why?
|
| Protective Factors | 4 | 2020 | 20 | 0.150 |
Why?
|
| Thinness | 1 | 2017 | 4 | 0.150 |
Why?
|
| RNA, Untranslated | 1 | 2017 | 3 | 0.150 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 10 | 0.150 |
Why?
|
| Nurse Clinicians | 1 | 1997 | 25 | 0.150 |
Why?
|
| Basal Nucleus of Meynert | 3 | 2002 | 7 | 0.150 |
Why?
|
| Fragile X Syndrome | 1 | 2020 | 190 | 0.150 |
Why?
|
| Sexual Behavior | 1 | 2017 | 61 | 0.150 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2005 | 3 | 0.150 |
Why?
|
| Sensation | 1 | 2017 | 17 | 0.150 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2017 | 3 | 0.140 |
Why?
|
| Central Nervous System | 2 | 2017 | 56 | 0.140 |
Why?
|
| Glutamic Acid | 3 | 2007 | 33 | 0.140 |
Why?
|
| Functional Food | 1 | 2017 | 2 | 0.140 |
Why?
|
| Olfactory Cortex | 1 | 2016 | 1 | 0.140 |
Why?
|
| Synaptic Transmission | 3 | 2019 | 45 | 0.140 |
Why?
|
| Family Conflict | 1 | 2016 | 3 | 0.140 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 10 | 0.140 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2016 | 4 | 0.140 |
Why?
|
| Symporters | 1 | 2016 | 5 | 0.140 |
Why?
|
| HIV-1 | 1 | 2020 | 456 | 0.140 |
Why?
|
| Ascorbic Acid | 4 | 2020 | 35 | 0.140 |
Why?
|
| Axonal Transport | 1 | 2016 | 8 | 0.140 |
Why?
|
| Personality Development | 1 | 2016 | 6 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 79 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2017 | 98 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 54 | 0.140 |
Why?
|
| Subcellular Fractions | 2 | 2008 | 16 | 0.140 |
Why?
|
| Receptors, LDL | 2 | 2007 | 7 | 0.140 |
Why?
|
| Dietary Supplements | 2 | 2015 | 63 | 0.140 |
Why?
|
| Pattern Recognition, Visual | 3 | 2005 | 31 | 0.140 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 5 | 0.140 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 14 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 190 | 0.140 |
Why?
|
| Zinc Fingers | 1 | 2016 | 12 | 0.140 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 1 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 344 | 0.140 |
Why?
|
| Visual Acuity | 2 | 2007 | 52 | 0.140 |
Why?
|
| Vital Capacity | 3 | 2022 | 12 | 0.140 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2016 | 6 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2023 | 323 | 0.140 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2012 | 31 | 0.140 |
Why?
|
| Biostatistics | 1 | 2016 | 6 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 189 | 0.140 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 13 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 25 | 0.130 |
Why?
|
| Electroencephalography | 2 | 2014 | 136 | 0.130 |
Why?
|
| Mercury | 1 | 2016 | 9 | 0.130 |
Why?
|
| Somatoform Disorders | 1 | 2016 | 20 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2016 | 104 | 0.130 |
Why?
|
| Fetus | 1 | 2016 | 59 | 0.130 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 3 | 0.130 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 6 | 0.130 |
Why?
|
| Whole Genome Sequencing | 3 | 2021 | 5 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2015 | 9 | 0.130 |
Why?
|
| Exosomes | 1 | 2015 | 4 | 0.130 |
Why?
|
| Neuroprotective Agents | 3 | 2015 | 59 | 0.130 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2015 | 5 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 209 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 44 | 0.130 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2021 | 7 | 0.130 |
Why?
|
| Micronutrients | 1 | 2015 | 4 | 0.130 |
Why?
|
| Food, Formulated | 1 | 2015 | 6 | 0.130 |
Why?
|
| Plasma | 1 | 2015 | 34 | 0.130 |
Why?
|
| Adiposity | 1 | 2016 | 45 | 0.130 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2015 | 3 | 0.130 |
Why?
|
| Visceral Afferents | 1 | 2015 | 4 | 0.130 |
Why?
|
| Computer Simulation | 6 | 2020 | 222 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2014 | 34 | 0.130 |
Why?
|
| Cholinergic Antagonists | 2 | 2013 | 12 | 0.130 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2015 | 8 | 0.130 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 523 | 0.130 |
Why?
|
| Presynaptic Terminals | 3 | 2016 | 16 | 0.130 |
Why?
|
| Bias | 3 | 2016 | 36 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 36 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 20 | 0.130 |
Why?
|
| HMGN1 Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
| Fractals | 3 | 2019 | 22 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2012 | 59 | 0.120 |
Why?
|
| Serine Endopeptidases | 2 | 2017 | 16 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 109 | 0.120 |
Why?
|
| Caspases | 2 | 2005 | 33 | 0.120 |
Why?
|
| Synucleins | 2 | 2013 | 7 | 0.120 |
Why?
|
| Early Diagnosis | 4 | 2020 | 69 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 2012 | 3 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2015 | 12 | 0.120 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Life Change Events | 1 | 2014 | 38 | 0.120 |
Why?
|
| Receptor, EphA1 | 2 | 2012 | 4 | 0.120 |
Why?
|
| Multiple System Atrophy | 1 | 2015 | 44 | 0.120 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2014 | 2 | 0.120 |
Why?
|
| Preoptic Area | 1 | 2014 | 6 | 0.120 |
Why?
|
| Acetylcholine | 3 | 2005 | 12 | 0.120 |
Why?
|
| Epidemiologic Research Design | 2 | 2012 | 16 | 0.120 |
Why?
|
| DNA | 2 | 2023 | 124 | 0.120 |
Why?
|
| Empathy | 1 | 2014 | 40 | 0.120 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 11 | 0.120 |
Why?
|
| Sensation Disorders | 1 | 2014 | 13 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 67 | 0.120 |
Why?
|
| Sulfonylurea Receptors | 1 | 2014 | 3 | 0.120 |
Why?
|
| Glucuronidase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Neuroglia | 3 | 2018 | 39 | 0.120 |
Why?
|
| Troponin T | 1 | 2014 | 4 | 0.120 |
Why?
|
| Obesity | 3 | 2015 | 304 | 0.120 |
Why?
|
| Erythrocyte Indices | 1 | 2014 | 5 | 0.120 |
Why?
|
| Image Enhancement | 2 | 2013 | 60 | 0.120 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 14 | 0.120 |
Why?
|
| gamma-Tocopherol | 1 | 2014 | 8 | 0.120 |
Why?
|
| Preventive Medicine | 1 | 2014 | 12 | 0.120 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 11 | 0.120 |
Why?
|
| Patient Admission | 1 | 2014 | 31 | 0.120 |
Why?
|
| Neuropil Threads | 3 | 2007 | 4 | 0.120 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 8 | 0.120 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 12 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 43 | 0.110 |
Why?
|
| Medicare Part D | 1 | 2013 | 8 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 67 | 0.110 |
Why?
|
| Telemetry | 1 | 2013 | 11 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 45 | 0.110 |
Why?
|
| Delusions | 2 | 2005 | 11 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 6 | 0.110 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Patient Selection | 2 | 2012 | 246 | 0.110 |
Why?
|
| Accidents, Traffic | 2 | 2012 | 14 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 59 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2014 | 150 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 5 | 0.110 |
Why?
|
| China | 3 | 2019 | 57 | 0.110 |
Why?
|
| Microcirculation | 2 | 2011 | 42 | 0.110 |
Why?
|
| PrPC Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
| Carbamazepine | 2 | 2005 | 13 | 0.110 |
Why?
|
| Mood Disorders | 2 | 2005 | 32 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2017 | 256 | 0.110 |
Why?
|
| Epilepsies, Partial | 2 | 2005 | 24 | 0.110 |
Why?
|
| Artifacts | 2 | 2023 | 34 | 0.110 |
Why?
|
| Time Perception | 1 | 2012 | 6 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 179 | 0.110 |
Why?
|
| Menopause | 1 | 2013 | 131 | 0.100 |
Why?
|
| Fear | 2 | 2017 | 47 | 0.100 |
Why?
|
| R-SNARE Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nerve Regeneration | 1 | 2012 | 14 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2012 | 25 | 0.100 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 12 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Licensure | 1 | 2012 | 10 | 0.100 |
Why?
|
| Eicosapentaenoic Acid | 3 | 2022 | 8 | 0.100 |
Why?
|
| Selection, Genetic | 1 | 2012 | 6 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 28 | 0.100 |
Why?
|
| Caspase 3 | 2 | 2010 | 30 | 0.100 |
Why?
|
| Receptors, Complement | 1 | 2012 | 5 | 0.100 |
Why?
|
| Bipolar Disorder | 3 | 2017 | 130 | 0.100 |
Why?
|
| Leukotriene B4 | 2 | 2022 | 5 | 0.100 |
Why?
|
| Environment | 1 | 2012 | 47 | 0.100 |
Why?
|
| Anticonvulsants | 2 | 2005 | 112 | 0.100 |
Why?
|
| Games, Experimental | 1 | 2011 | 9 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 19 | 0.100 |
Why?
|
| Likelihood Functions | 3 | 2017 | 28 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2020 | 79 | 0.100 |
Why?
|
| Endocytosis | 1 | 2011 | 17 | 0.100 |
Why?
|
| Spinal Cord Injuries | 1 | 2012 | 48 | 0.100 |
Why?
|
| Multigene Family | 3 | 2018 | 12 | 0.100 |
Why?
|
| Phlebotomy | 1 | 2011 | 4 | 0.100 |
Why?
|
| Transfection | 4 | 2013 | 127 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 63 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 60 | 0.100 |
Why?
|
| Cerebral Angiography | 1 | 2011 | 33 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 230 | 0.100 |
Why?
|
| Guanylate Kinases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Post-Synaptic Density | 1 | 2011 | 2 | 0.100 |
Why?
|
| Corticosterone | 1 | 2011 | 3 | 0.100 |
Why?
|
| Carnitine | 2 | 2022 | 8 | 0.100 |
Why?
|
| Receptor, trkA | 2 | 2001 | 9 | 0.100 |
Why?
|
| Aspirin | 2 | 2008 | 87 | 0.100 |
Why?
|
| Antibodies | 1 | 2011 | 67 | 0.100 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 14 | 0.100 |
Why?
|
| Peptidylprolyl Isomerase | 2 | 2010 | 7 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2023 | 83 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2015 | 48 | 0.100 |
Why?
|
| Population Dynamics | 3 | 2011 | 10 | 0.090 |
Why?
|
| Europe | 2 | 2021 | 80 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2014 | 328 | 0.090 |
Why?
|
| Parahippocampal Gyrus | 2 | 2002 | 8 | 0.090 |
Why?
|
| Glucose | 3 | 2022 | 65 | 0.090 |
Why?
|
| Wakefulness | 1 | 2011 | 81 | 0.090 |
Why?
|
| Terahertz Imaging | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 23 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2011 | 101 | 0.090 |
Why?
|
| Semantics | 2 | 2008 | 20 | 0.090 |
Why?
|
| Lysosomes | 2 | 2021 | 25 | 0.090 |
Why?
|
| Insulysin | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2010 | 38 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 159 | 0.090 |
Why?
|
| Metalloendopeptidases | 1 | 2010 | 25 | 0.090 |
Why?
|
| Species Specificity | 2 | 2020 | 73 | 0.090 |
Why?
|
| Fitness Trackers | 2 | 2021 | 15 | 0.090 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2010 | 2 | 0.090 |
Why?
|
| Adenosine Triphosphatases | 1 | 2010 | 7 | 0.090 |
Why?
|
| Telephone | 1 | 2010 | 26 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2020 | 427 | 0.090 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2010 | 7 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2020 | 25 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Electric Impedance | 2 | 2021 | 25 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 149 | 0.090 |
Why?
|
| Single-Blind Method | 4 | 2014 | 120 | 0.090 |
Why?
|
| Atlases as Topic | 2 | 2021 | 7 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2021 | 10 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1994 | 817 | 0.090 |
Why?
|
| Synaptic Vesicles | 2 | 2020 | 4 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 5 | 2008 | 271 | 0.090 |
Why?
|
| Intelligence Tests | 2 | 2021 | 16 | 0.090 |
Why?
|
| Neurogenesis | 2 | 2020 | 12 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2020 | 56 | 0.090 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 19 | 0.090 |
Why?
|
| Drug Design | 1 | 2009 | 31 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 29 | 0.090 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 167 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 33 | 0.090 |
Why?
|
| Exome | 2 | 2021 | 9 | 0.080 |
Why?
|
| Sterols | 1 | 2009 | 5 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 2 | 2006 | 38 | 0.080 |
Why?
|
| Mechanoreceptors | 1 | 2009 | 7 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2020 | 11 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2009 | 14 | 0.080 |
Why?
|
| Dystonia | 1 | 1989 | 40 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 79 | 0.080 |
Why?
|
| Proprioception | 1 | 2009 | 19 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 61 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2010 | 38 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2009 | 16 | 0.080 |
Why?
|
| Sirtuins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1989 | 50 | 0.080 |
Why?
|
| Immunoprecipitation | 3 | 2014 | 23 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 31 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 32 | 0.080 |
Why?
|
| Dopamine | 1 | 2009 | 149 | 0.080 |
Why?
|
| Ergometry | 1 | 2008 | 3 | 0.080 |
Why?
|
| Differential Threshold | 1 | 2008 | 3 | 0.080 |
Why?
|
| Joints | 1 | 2009 | 99 | 0.080 |
Why?
|
| Nervous System | 1 | 1988 | 10 | 0.080 |
Why?
|
| Dendrites | 2 | 2010 | 15 | 0.080 |
Why?
|
| Extremities | 1 | 2008 | 33 | 0.080 |
Why?
|
| ADAMTS Proteins | 2 | 2019 | 5 | 0.080 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2019 | 5 | 0.080 |
Why?
|
| Claudin-5 | 2 | 2021 | 3 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2020 | 152 | 0.080 |
Why?
|
| Versicans | 2 | 2019 | 17 | 0.080 |
Why?
|
| Physical Therapy Modalities | 2 | 2022 | 78 | 0.080 |
Why?
|
| Primary Cell Culture | 2 | 2018 | 21 | 0.080 |
Why?
|
| Complement C9 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Complement C3b | 1 | 2008 | 2 | 0.080 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 49 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2008 | 22 | 0.080 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cell Line | 2 | 2019 | 304 | 0.080 |
Why?
|
| Encephalitis | 1 | 2008 | 18 | 0.080 |
Why?
|
| Microarray Analysis | 2 | 2019 | 9 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 27 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2020 | 11 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2008 | 14 | 0.080 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 30 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 1988 | 55 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2020 | 215 | 0.070 |
Why?
|
| Pedigree | 3 | 2016 | 75 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 43 | 0.070 |
Why?
|
| Mass Screening | 1 | 2009 | 186 | 0.070 |
Why?
|
| Receptors, Erythropoietin | 1 | 2007 | 2 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 467 | 0.070 |
Why?
|
| Cholesterol | 2 | 2022 | 55 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 34 | 0.070 |
Why?
|
| Chemical Fractionation | 2 | 2004 | 7 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 57 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2016 | 70 | 0.070 |
Why?
|
| Observation | 1 | 2007 | 16 | 0.070 |
Why?
|
| Frontotemporal Dementia | 2 | 2019 | 14 | 0.070 |
Why?
|
| Health Planning | 1 | 2007 | 5 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2020 | 59 | 0.070 |
Why?
|
| Lipase | 1 | 2006 | 6 | 0.070 |
Why?
|
| Lipid Bilayers | 3 | 1991 | 52 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2007 | 24 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2007 | 35 | 0.070 |
Why?
|
| Anesthetics | 3 | 1991 | 24 | 0.070 |
Why?
|
| Selenium | 2 | 2017 | 7 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2022 | 60 | 0.070 |
Why?
|
| Cellular Senescence | 2 | 2019 | 19 | 0.070 |
Why?
|
| Molecular Sequence Annotation | 2 | 2016 | 6 | 0.070 |
Why?
|
| Interneurons | 1 | 2006 | 6 | 0.070 |
Why?
|
| Caenorhabditis elegans | 2 | 2019 | 7 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2006 | 14 | 0.070 |
Why?
|
| Urban Health | 1 | 2006 | 23 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 35 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 688 | 0.070 |
Why?
|
| Biotechnology | 1 | 2005 | 3 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2005 | 44 | 0.070 |
Why?
|
| Sweden | 2 | 2016 | 10 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2015 | 16 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 6 | 0.060 |
Why?
|
| Confusion | 1 | 2005 | 12 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2005 | 41 | 0.060 |
Why?
|
| Binding Sites | 2 | 2017 | 75 | 0.060 |
Why?
|
| Animals, Genetically Modified | 2 | 2018 | 17 | 0.060 |
Why?
|
| Exons | 3 | 2013 | 37 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 78 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 41 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2005 | 8 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 135 | 0.060 |
Why?
|
| Pregnancy | 2 | 2020 | 403 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2005 | 18 | 0.060 |
Why?
|
| Parenting | 1 | 2006 | 73 | 0.060 |
Why?
|
| Alzheimer Vaccines | 1 | 2005 | 1 | 0.060 |
Why?
|
| Introns | 2 | 2015 | 16 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 136 | 0.060 |
Why?
|
| Logic | 1 | 2004 | 3 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2005 | 46 | 0.060 |
Why?
|
| Microsomes | 1 | 2004 | 16 | 0.060 |
Why?
|
| Maze Learning | 2 | 2016 | 17 | 0.060 |
Why?
|
| Neurites | 3 | 2010 | 13 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 3 | 2016 | 91 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2004 | 15 | 0.060 |
Why?
|
| Receptors, GABA-A | 1 | 2004 | 3 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2016 | 93 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2004 | 21 | 0.060 |
Why?
|
| Niacin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Institutionalization | 1 | 2004 | 2 | 0.060 |
Why?
|
| Superoxide Dismutase | 2 | 2021 | 20 | 0.060 |
Why?
|
| Cell Death | 3 | 2014 | 61 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 90 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 23 | 0.060 |
Why?
|
| Auditory Perception | 2 | 2017 | 36 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 14 | 0.060 |
Why?
|
| Prejudice | 1 | 2004 | 41 | 0.060 |
Why?
|
| Speech Perception | 1 | 2004 | 47 | 0.060 |
Why?
|
| Meninges | 1 | 2023 | 8 | 0.060 |
Why?
|
| Government Agencies | 1 | 2023 | 4 | 0.060 |
Why?
|
| Software | 2 | 2019 | 73 | 0.060 |
Why?
|
| Base Sequence | 1 | 2023 | 133 | 0.060 |
Why?
|
| Protein Binding | 2 | 2016 | 125 | 0.060 |
Why?
|
| Minority Groups | 2 | 2020 | 74 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2003 | 19 | 0.060 |
Why?
|
| Embryo, Mammalian | 2 | 2016 | 30 | 0.060 |
Why?
|
| RNA, Small Nuclear | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2023 | 13 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2003 | 22 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2023 | 4 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 34 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 27 | 0.050 |
Why?
|
| Behavior | 2 | 1994 | 24 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 337 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 18 | 0.050 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2022 | 8 | 0.050 |
Why?
|
| Receptors, GABA | 2 | 2017 | 5 | 0.050 |
Why?
|
| Copper | 1 | 2022 | 16 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 42 | 0.050 |
Why?
|
| Ganglia, Spinal | 1 | 2023 | 68 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 47 | 0.050 |
Why?
|
| Macrophages | 1 | 2023 | 137 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2012 | 25 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 10 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2022 | 4 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2013 | 19 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 24 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Bone Density | 1 | 2023 | 152 | 0.050 |
Why?
|
| Thoracic Vertebrae | 2 | 2015 | 115 | 0.050 |
Why?
|
| Zebrafish | 1 | 2022 | 18 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 117 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2022 | 7 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 11 | 0.050 |
Why?
|
| Protein Phosphatase 2 | 1 | 2022 | 1 | 0.050 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 7 | 0.050 |
Why?
|
| Silver Staining | 1 | 2002 | 5 | 0.050 |
Why?
|
| Thiazoles | 2 | 2013 | 31 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 103 | 0.050 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nucleotides | 1 | 2021 | 1 | 0.050 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2021 | 1 | 0.050 |
Why?
|
| Bethanechol Compounds | 2 | 1993 | 5 | 0.050 |
Why?
|
| Retinoid X Receptors | 1 | 2021 | 3 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 26 | 0.050 |
Why?
|
| Amino Acids | 1 | 2021 | 22 | 0.050 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 2 | 2017 | 8 | 0.050 |
Why?
|
| Oxylipins | 1 | 2021 | 1 | 0.050 |
Why?
|
| Endocannabinoids | 1 | 2021 | 3 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 29 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 35 | 0.050 |
Why?
|
| Caffeine | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fasting | 1 | 2021 | 13 | 0.050 |
Why?
|
| Eating | 1 | 2022 | 55 | 0.050 |
Why?
|
| North America | 1 | 2021 | 39 | 0.050 |
Why?
|
| Arthralgia | 1 | 2023 | 133 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2021 | 12 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 140 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 28 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 19 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 1 | 2021 | 9 | 0.050 |
Why?
|
| Pharmacoepidemiology | 1 | 2021 | 5 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 223 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2021 | 1 | 0.050 |
Why?
|
| Spatial Processing | 1 | 2021 | 8 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 35 | 0.050 |
Why?
|
| Serotonin | 1 | 2021 | 37 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 14 | 0.050 |
Why?
|
| Poly T | 1 | 2021 | 3 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2021 | 52 | 0.050 |
Why?
|
| Ion Channels | 1 | 2023 | 191 | 0.050 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2021 | 2 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 21 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2021 | 18 | 0.050 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2021 | 8 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2021 | 7 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2021 | 16 | 0.050 |
Why?
|
| New York City | 1 | 2021 | 17 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2021 | 204 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2020 | 16 | 0.050 |
Why?
|
| Proteolysis | 1 | 2020 | 13 | 0.050 |
Why?
|
| Language Disorders | 1 | 2000 | 10 | 0.050 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 21 | 0.050 |
Why?
|
| HLA-DRB1 Chains | 1 | 2020 | 4 | 0.050 |
Why?
|
| Attitude to Death | 1 | 2020 | 16 | 0.050 |
Why?
|
| Y Chromosome | 1 | 2020 | 1 | 0.050 |
Why?
|
| X Chromosome | 1 | 2020 | 9 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 35 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 14 | 0.050 |
Why?
|
| Observer Variation | 2 | 1997 | 118 | 0.050 |
Why?
|
| Testis | 1 | 2020 | 12 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2021 | 110 | 0.050 |
Why?
|
| Late Onset Disorders | 1 | 2020 | 7 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2021 | 105 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 35 | 0.050 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 4 | 0.050 |
Why?
|
| Sphenoid Bone | 1 | 2020 | 6 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 45 | 0.050 |
Why?
|
| Sella Turcica | 1 | 2020 | 6 | 0.050 |
Why?
|
| Vertigo | 1 | 2000 | 8 | 0.040 |
Why?
|
| Carotenoids | 1 | 2020 | 13 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 18 | 0.040 |
Why?
|
| Protein Transport | 2 | 2011 | 40 | 0.040 |
Why?
|
| Skull | 1 | 2020 | 26 | 0.040 |
Why?
|
| POU Domain Factors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Sample Size | 1 | 2020 | 25 | 0.040 |
Why?
|
| Meningioma | 1 | 2020 | 20 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 195 | 0.040 |
Why?
|
| Red Meat | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cheese | 1 | 2020 | 1 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2020 | 1 | 0.040 |
Why?
|
| Aggression | 2 | 2004 | 32 | 0.040 |
Why?
|
| Flavonoids | 1 | 2020 | 21 | 0.040 |
Why?
|
| Kaempferols | 1 | 2020 | 13 | 0.040 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 4 | 0.040 |
Why?
|
| Quercetin | 1 | 2020 | 16 | 0.040 |
Why?
|
| Wine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 7 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 63 | 0.040 |
Why?
|
| Permeability | 1 | 2020 | 139 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 86 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 2 | 0.040 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sampling Studies | 3 | 2005 | 29 | 0.040 |
Why?
|
| Lung Volume Measurements | 1 | 2019 | 5 | 0.040 |
Why?
|
| Substantia Innominata | 1 | 1999 | 3 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2020 | 26 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 44 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 1999 | 10 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 23 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2014 | 52 | 0.040 |
Why?
|
| Heredity | 1 | 2019 | 6 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Random Allocation | 2 | 1999 | 147 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 25 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2020 | 132 | 0.040 |
Why?
|
| Students | 1 | 2020 | 40 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2019 | 1 | 0.040 |
Why?
|
| Ventral Striatum | 1 | 2019 | 1 | 0.040 |
Why?
|
| Leptin | 1 | 2019 | 24 | 0.040 |
Why?
|
| Theta Rhythm | 1 | 2019 | 4 | 0.040 |
Why?
|
| Nestin | 1 | 2019 | 3 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2019 | 9 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2019 | 42 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2019 | 11 | 0.040 |
Why?
|
| Dopaminergic Neurons | 1 | 2020 | 45 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 386 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Spatial Navigation | 1 | 2018 | 3 | 0.040 |
Why?
|
| Sigmoidoscopy | 1 | 1998 | 8 | 0.040 |
Why?
|
| Enema | 1 | 1998 | 3 | 0.040 |
Why?
|
| Vocabulary | 1 | 1999 | 14 | 0.040 |
Why?
|
| Systems Integration | 1 | 2018 | 5 | 0.040 |
Why?
|
| Systems Biology | 1 | 2018 | 7 | 0.040 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2018 | 12 | 0.040 |
Why?
|
| Time and Motion Studies | 1 | 2018 | 18 | 0.040 |
Why?
|
| DNA Repair | 1 | 2018 | 7 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 17 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 8 | 0.040 |
Why?
|
| Home Care Services | 1 | 1998 | 21 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 18 | 0.040 |
Why?
|
| Reproduction | 1 | 2018 | 12 | 0.040 |
Why?
|
| Acute Disease | 3 | 2005 | 232 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2018 | 30 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 70 | 0.040 |
Why?
|
| Threonine | 1 | 2018 | 7 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 1 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 9 | 0.040 |
Why?
|
| Alanine | 1 | 2018 | 10 | 0.040 |
Why?
|
| Language Tests | 2 | 2013 | 29 | 0.040 |
Why?
|
| Gene Library | 1 | 2018 | 8 | 0.040 |
Why?
|
| Nutritional Status | 2 | 2011 | 46 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2015 | 499 | 0.040 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2017 | 2 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2017 | 9 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2017 | 7 | 0.040 |
Why?
|
| Philadelphia | 1 | 2017 | 5 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2013 | 635 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2018 | 30 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 53 | 0.040 |
Why?
|
| Prisoners | 1 | 2017 | 10 | 0.040 |
Why?
|
| France | 1 | 2017 | 21 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2017 | 31 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2012 | 42 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2017 | 2 | 0.040 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 46 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 1 | 2017 | 8 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 13 | 0.040 |
Why?
|
| Netrin Receptors | 1 | 2017 | 5 | 0.040 |
Why?
|
| Solubility | 1 | 2017 | 36 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Research | 1 | 2017 | 55 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 12 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2017 | 3 | 0.040 |
Why?
|
| NFI Transcription Factors | 1 | 2017 | 1 | 0.040 |
Why?
|
| Peroxisomal Bifunctional Enzyme | 1 | 2017 | 1 | 0.040 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2017 | 5 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 27 | 0.040 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Liver | 1 | 2018 | 184 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2016 | 1 | 0.040 |
Why?
|
| Polycomb-Group Proteins | 1 | 2016 | 1 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Vitamins | 1 | 2017 | 20 | 0.040 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 3 | 0.040 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2016 | 4 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 13 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 11 | 0.040 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1996 | 2 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 84 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2016 | 2 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 12 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 10 | 0.030 |
Why?
|
| Neurology | 1 | 1997 | 79 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 20 | 0.030 |
Why?
|
| PubMed | 1 | 2016 | 13 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 7 | 0.030 |
Why?
|
| Neuroprotection | 1 | 2016 | 4 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 47 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 68 | 0.030 |
Why?
|
| Protein Folding | 1 | 2016 | 24 | 0.030 |
Why?
|
| COS Cells | 1 | 2016 | 35 | 0.030 |
Why?
|
| Organic Anion Transporters | 1 | 2016 | 1 | 0.030 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2016 | 1 | 0.030 |
Why?
|
| Arterioles | 1 | 2016 | 14 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2004 | 344 | 0.030 |
Why?
|
| England | 1 | 2016 | 13 | 0.030 |
Why?
|
| DNA Primers | 2 | 2010 | 53 | 0.030 |
Why?
|
| Diet Records | 1 | 2016 | 7 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 15 | 0.030 |
Why?
|
| Weight Loss | 1 | 1997 | 116 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 9 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 18 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 225 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2015 | 17 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 4 | 0.030 |
Why?
|
| Acetamides | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 16 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2015 | 23 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 97 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 47 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Scotland | 1 | 2015 | 7 | 0.030 |
Why?
|
| Sacrum | 1 | 2015 | 29 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2015 | 23 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2014 | 6 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 3 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2015 | 26 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 43 | 0.030 |
Why?
|
| Receptors, Kainic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2014 | 2 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Phonetics | 1 | 2014 | 10 | 0.030 |
Why?
|
| Galanin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 39 | 0.030 |
Why?
|
| Occupations | 2 | 2005 | 14 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 365 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 2 | 1991 | 8 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 4 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2014 | 22 | 0.030 |
Why?
|
| Phagosomes | 1 | 2014 | 3 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 18 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| New York | 1 | 2014 | 10 | 0.030 |
Why?
|
| Glutamates | 2 | 2011 | 17 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2014 | 59 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 1993 | 12 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 63 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 29 | 0.030 |
Why?
|
| Antigens | 1 | 1993 | 27 | 0.030 |
Why?
|
| Circle of Willis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2004 | 54 | 0.030 |
Why?
|
| Sulfites | 1 | 2013 | 1 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 65 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2015 | 158 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 32 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 3 | 0.030 |
Why?
|
| Dextrans | 1 | 2013 | 6 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 13 | 0.030 |
Why?
|
| Religion | 1 | 2013 | 41 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 55 | 0.030 |
Why?
|
| Epitopes | 2 | 2004 | 88 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Serine | 1 | 2013 | 11 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2013 | 28 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 345 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 116 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 15 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 88 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2003 | 34 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2014 | 227 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2012 | 4 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2013 | 111 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 89 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 25 | 0.030 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2012 | 4 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1992 | 6 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 48 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 303 | 0.030 |
Why?
|
| Phosphoserine | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cerebellar Cortex | 1 | 2012 | 7 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 36 | 0.030 |
Why?
|
| Dependovirus | 1 | 2012 | 37 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2012 | 63 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 1 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 1 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Autoradiography | 1 | 2012 | 11 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1992 | 43 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2012 | 60 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1992 | 17 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 7 | 1 | 2011 | 3 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 1992 | 15 | 0.020 |
Why?
|
| Secretory Pathway | 1 | 2011 | 1 | 0.020 |
Why?
|
| Clathrin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1992 | 58 | 0.020 |
Why?
|
| Insecticides | 1 | 1991 | 3 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 380 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2011 | 52 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1992 | 64 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 443 | 0.020 |
Why?
|
| American Heart Association | 1 | 2011 | 30 | 0.020 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2011 | 5 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2012 | 33 | 0.020 |
Why?
|
| CELF Proteins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2011 | 106 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 7 | 0.020 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Dementia, Multi-Infarct | 1 | 1990 | 1 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 1990 | 3 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 5 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 1991 | 20 | 0.020 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2010 | 1 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 65 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2010 | 8 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 13 | 0.020 |
Why?
|
| Neurofibrils | 1 | 2010 | 2 | 0.020 |
Why?
|
| Valosin Containing Protein | 1 | 2010 | 1 | 0.020 |
Why?
|
| Caspase 7 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 43 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 41 | 0.020 |
Why?
|
| Anesthetics, Local | 1 | 1991 | 97 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 92 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 13 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 7 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2009 | 56 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Convulsants | 1 | 2008 | 1 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2008 | 5 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2008 | 7 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2008 | 9 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2008 | 9 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 2009 | 12 | 0.020 |
Why?
|
| Propionates | 1 | 2008 | 12 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2008 | 14 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tissue Extracts | 1 | 2008 | 12 | 0.020 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1988 | 4 | 0.020 |
Why?
|
| Cytosol | 1 | 2008 | 63 | 0.020 |
Why?
|
| Respiration | 1 | 1988 | 35 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 19 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2012 | 382 | 0.020 |
Why?
|
| Bromocriptine | 1 | 1987 | 7 | 0.020 |
Why?
|
| Myoclonus | 1 | 1987 | 24 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1987 | 6 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 1987 | 15 | 0.020 |
Why?
|
| Microtubules | 1 | 2007 | 28 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 269 | 0.020 |
Why?
|
| Proxy | 1 | 2006 | 2 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2006 | 7 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 47 | 0.020 |
Why?
|
| Piperazines | 1 | 1987 | 91 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 14 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 66 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 12 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2005 | 5 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 11 | 0.020 |
Why?
|
| Vidarabine | 1 | 2005 | 12 | 0.020 |
Why?
|
| Melphalan | 1 | 2005 | 16 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 16 | 0.020 |
Why?
|
| Fever | 1 | 2005 | 42 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2005 | 139 | 0.020 |
Why?
|
| Kentucky | 1 | 2005 | 1 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 104 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 118 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 246 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 208 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2004 | 8 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 10 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2004 | 13 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2005 | 59 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 32 | 0.010 |
Why?
|
| Sick Role | 1 | 2004 | 13 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 52 | 0.010 |
Why?
|
| Play and Playthings | 1 | 2003 | 8 | 0.010 |
Why?
|
| Censuses | 1 | 2003 | 5 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 7 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 109 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 260 | 0.010 |
Why?
|
| Population | 1 | 2002 | 3 | 0.010 |
Why?
|
| Casein Kinases | 1 | 2002 | 2 | 0.010 |
Why?
|
| beta Carotene | 1 | 2002 | 7 | 0.010 |
Why?
|
| Hypotension | 1 | 2002 | 32 | 0.010 |
Why?
|
| Dominance, Cerebral | 1 | 2002 | 21 | 0.010 |
Why?
|
| Cholinergic Fibers | 1 | 2002 | 8 | 0.010 |
Why?
|
| Arousal | 1 | 2002 | 45 | 0.010 |
Why?
|
| Paired-Associate Learning | 1 | 2001 | 4 | 0.010 |
Why?
|
| Systole | 1 | 2001 | 20 | 0.010 |
Why?
|
| Cell Size | 1 | 2001 | 8 | 0.010 |
Why?
|
| Diastole | 1 | 2001 | 36 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 22 | 0.010 |
Why?
|
| Thermodynamics | 2 | 1991 | 43 | 0.010 |
Why?
|
| Neurobehavioral Manifestations | 1 | 2000 | 1 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2000 | 36 | 0.010 |
Why?
|
| Vesicular Acetylcholine Transport Proteins | 1 | 1999 | 1 | 0.010 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 1 | 1999 | 1 | 0.010 |
Why?
|
| Superoxides | 1 | 1999 | 26 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 167 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1998 | 13 | 0.010 |
Why?
|
| Self Administration | 1 | 1998 | 35 | 0.010 |
Why?
|
| Dentate Gyrus | 1 | 1997 | 8 | 0.010 |
Why?
|
| Body Height | 1 | 1997 | 34 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 246 | 0.010 |
Why?
|
| Caregivers | 1 | 1997 | 156 | 0.010 |
Why?
|
| Irritable Mood | 1 | 1991 | 6 | 0.010 |
Why?
|
| Psychomotor Agitation | 1 | 1991 | 14 | 0.010 |
Why?
|
| Biological Transport | 1 | 1991 | 44 | 0.010 |
Why?
|
| Attitude | 1 | 1991 | 32 | 0.010 |
Why?
|
| Temperature | 1 | 1991 | 74 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1991 | 59 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1991 | 43 | 0.010 |
Why?
|
| Radiography | 1 | 1992 | 695 | 0.010 |
Why?
|
| Bethanechol | 1 | 1989 | 4 | 0.010 |
Why?
|
| N-Methylaspartate | 1 | 1987 | 4 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 31 | 0.000 |
Why?
|
| Cyclic GMP | 1 | 1987 | 11 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1987 | 51 | 0.000 |
Why?
|
| Kinetics | 1 | 1987 | 227 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1987 | 99 | 0.000 |
Why?
|
| Seizures | 1 | 1987 | 94 | 0.000 |
Why?
|